The combination of venetoclax (VEN) and a hypomethylating agent (HMA) is a standard of care for patients with AML and higher-risk myelodysplastic syndromes (MDS). However, real-world outcomes data ...
Researchers compared intensive chemotherapy with single-agent clofarabine in fit older adults with newly diagnosed AML.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results